StreetInsider.com News Articles

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- These companies are stepping into the market spotlight with very different catalysts: NeOnc (NASDAQ:NTHI) is drawing Wall Street attention around its brain-cancer pipeline and a $20 price target; Profusa (NASDAQ:PFSA) is advancing the regulatory path for its Lumee Oxygen Platform; Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) is expanding into blockchain-powered ecosystem finance through its MindWave Innovations subsidiary; and Greenland Energy Company (NASDAQ:GLND) has extended the timeline for its Jameson Land exploration program in East Greenland.

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Profusa receives ISO 13485 certification decision for Lumee platform

Thu, 24 Sep 2026 07:30:13 -0400

Profusa, Inc. (Nasdaq: PFSA) announced it has received a positive decision from GMED, a notified body under the European Union Medical Device Regulation (MDR), regarding certification of its quality management system to ISO 13485.

The Berkeley, California-based company said it continues to work with GMED toward completion of the remaining MDR conformity assessment activities for its Lumee Oxygen Platform. Successful completion of those activities would support issuance of an MDR certificate and allow the company to apply a CE mark to the product, which signifies compliance with safety, health, and environmental protection standards required for sale across the 27 EU member

Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October

Thu, 24 Sep 2026 07:30:00 -0400

BERKELEY, CA, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensor technologies today announced that the Company has received a positive decision from GMED regarding certification of its quality management system to ISO 13485. GMED is a notified body designated under the European Union Medical Device Regulation (MDR). The Company continues to work with GMED toward completion of the remaining applicable MDR conformity assessment activities for the Lumee® Oxygen Platform. Successful completion of these activities would support issuance of the applicable MDR certificate and the Company's subsequent CE

Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October

Thu, 24 Sep 2026 07:30:00 -0400

Profusa regains Nasdaq compliance, faces one-year monitoring period

Tue, 15 Sep 2026 06:01:20 -0400

Profusa, Inc. (Nasdaq: PFSA) announced it received a letter from the Nasdaq Stock Market on Sept. 9, 2026, confirming the company has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule, and Nasdaq Listing Rule 5550(b)(1), the Equity Rule.

The company remains subject to a one-year Mandatory Panel Monitor. If Profusa fails to satisfy the equity rule during this period, Nasdaq will issue a delist determination without providing the company an opportunity to submit a compliance plan. Profusa may appeal such a determination by requesting a hearing, which would stay further action by Nasdaq until the hearing is held

Profusa, Inc. Receives Nasdaq Compliance Determination

Tue, 15 Sep 2026 06:00:00 -0400

Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has demonstrated compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”).

The Company remains subject to a one-year Mandatory Panel Monitor (the “Monitoring Period”). If during the Monitoring Period the Company fails to satisfy the equity rule, the company will not be provided the

Profusa, Inc. Receives Nasdaq Compliance Determination

Tue, 15 Sep 2026 06:00:00 -0400

Profusa regains Nasdaq compliance after reverse stock split issue

Mon, 31 Aug 2026 08:50:34 -0400

Profusa, Inc. (NASDAQ: PFSA) announced it received a notice from the Listing Qualifications Department of the Nasdaq Stock Market stating that following the company's 1-for-4 reverse stock split, its publicly held shares fell below the 500,000-share minimum required under Nasdaq Listing Rule 5550(a)(4).

The deficiency was identified on Aug. 14, 2026. After correspondence between the company and Nasdaq, the exchange determined that Profusa had returned to compliance with the rule as of Aug. 21, 2026, and closed its review.

According to the announcement, the notice has no effect on the listing or trading of the company's shares, which continue to trade on

Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement

Mon, 31 Aug 2026 08:50:00 -0400

Berkeley, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced that it has received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on August 14, 2026, following the effectiveness of the Company’s 1-for-4 reverse stock split, the Company had less than the 500,000 publicly held shares required under Nasdaq Listing Rule 5550(a)(4) (the “Rule”). The Notice further stated that based on the Company’s correspondence with Nasdaq on August 21, 2026, Nasdaq has determined that the Company complies with the Rule as

Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement

Mon, 31 Aug 2026 08:50:00 -0400

Profusa reports Q2 2026 loss, advances G3 Vision Labs deal

Thu, 20 Aug 2026 08:32:24 -0400

Profusa, Inc. (Nasdaq: PFSA) reported a net loss of $8.8 million for the three months ended June 30, 2026, compared to a net loss of $2.3 million in the same period a year earlier, according to a company press release.

For the six months ended June 30, 2026, the net loss was $12.2 million, up from $5.1 million for the same period in 2025. Cash on hand at June 30, 2026 was $719,000, with total assets of $1.0 million and total liabilities of $28.2 million. The total stockholders' deficit stood at $27.1 million as of June 30, 2026.

The company said stockholders'

Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company

Thu, 20 Aug 2026 08:30:00 -0400

Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock

Sufficient working capital obtained to fund operations for near term

PCAOB audited 2024 and 2025 financials of G3 and Subsidiaries are expected by mid-September

Reverse stock split successfully executed

August 20, 2026

BERKELEY, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensor technologies, previously announced the signing of an Option Agreement (the “Agreement”) which provides Profusa the

Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company

Thu, 20 Aug 2026 08:30:00 -0400

Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock

Sufficient working capital obtained to fund operations for near term

PCAOB audited 2024 and 2025 financials of G3 and Subsidiaries are expected by mid-September

Reverse stock split successfully executed

August 20, 2026

Profusa announces 1-for-4 reverse stock split effective Aug. 17

Thu, 13 Aug 2026 07:00:30 -0400

Profusa, Inc. (Nasdaq: PFSA), a Berkeley, California-based digital health company, announced a 1-for-4 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on Aug. 17, 2026.

The company filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of Delaware to effect the split. Profusa's common stock will begin trading on the Nasdaq Capital Market on a post-split basis on Aug. 17, 2026, under the existing ticker symbol "PFSA" with a new CUSIP number of 74319X405.

As a result of the reverse stock split, every four shares of common stock will be

Profusa Announces 1-for-4 Reverse Stock Split

Thu, 13 Aug 2026 07:00:00 -0400

BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced that it ﬁled an amendment to its amended and restated certiﬁcate of incorporation with the Secretary of State of the State of Delaware to eﬀect a one-for-four (1:4) reverse stock split of its common stock. The reverse stock split will take eﬀect at 12:01 am (Eastern Time) on August 17, 2026, and the Company’s common stock will open for

Profusa Announces 1-for-4 Reverse Stock Split

Thu, 13 Aug 2026 07:00:00 -0400

Profusa signs option to acquire diagnostics firm G3 Vision Labs

Fri, 31 Jul 2026 17:15:13 -0400

Profusa, Inc. (Nasdaq: PFSA) has signed an option agreement that gives the company the right, but not the obligation, to acquire G3 Vision Labs, Inc. and its subsidiaries, Med Screen Laboratories Inc., Dominion Diagnostics LLC, and Acutis Diagnostics Inc., according to a press release.

G3 Vision Labs' 2025 net revenues are estimated at approximately $111 million, based on unaudited management information. G3 operates national CLIA-certified laboratories serving addiction treatment, pain management, and behavioral health providers.

The option is exercisable at any time before G3 delivers specified financial information and for 90 days thereafter. Key conditions for exercising the option include Profusa securing

Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs

Fri, 31 Jul 2026 17:15:00 -0400

BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligation, subject to satisfaction of the conditions described below, to acquire G3 Vision Labs, Inc. (“G3”) and its subsidiaries, Med Screen Laboratories Inc., Dominion Diagnostics LLC and Acutis Diagnostics Inc. G3's 2025 Net Revenues are estimated, based on unaudited management information, to be approximately $111 million. The Agreement formalizes the arrangement between Profusa and G3 that was

Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs

Fri, 31 Jul 2026 17:15:00 -0400

Profusa signs term sheet to acquire diagnostics firm with $111M revenue

Mon, 27 Jul 2026 06:00:19 -0400

Profusa, Inc. (Nasdaq: PFSA) has signed a non-binding term sheet to acquire a privately held, commercial-stage health diagnostics and toxicology testing company, according to a press release from the Berkeley, Calif.-based company.

The unnamed diagnostics company reported estimated 2025 net revenues of approximately $111 million, based on unaudited management information. It operates CLIA-certified and CAP/CLIA accredited national medical laboratories providing molecular diagnostic tests and toxicology testing, serving addiction treatment, pain management, and behavioral health providers.

If a definitive agreement is reached, Profusa would issue to the target company's stockholders shares of Profusa common stock equal to 19.99% of its then-outstanding common shares,